Borgaonkar S, Jain A, Bollina P, McLaren D B, Tulloch D, Kerr G R, Howard G C W
Urology Section, Edinburgh Cancer Centre, The Western General Hospital, UK.
Clin Oncol (R Coll Radiol). 2002 Apr;14(2):141-7. doi: 10.1053/clon.2002.0055.
The objective of this study was to review the results of our policy of primary radiotherapy (RT) and salvage cystectomy for transitional carcinoma (TCC) of the bladder in the light of changes in our radiotherapy planning procedure, in particular the introduction of CT planning. The case notes of 163 patients treated with radical radiotherapy using a CT planning technique were examined. The main endpoint for assessment was response at the time of the check cystoscopy 6 months after the completion of treatment. In addition survival was estimated by stage of disease and by response at the time of first cystoscopy. Patterns of relapse and time to relapse were analysed. All percentages quoted in the text use the initial 163 patients as the denominator. One hundred patients (61%) achieved a complete response. The complete response rate was significantly related to T stage at presentation being 90% for T1, 75% for T2, and 53% for T3 disease respectively. Of these patients 78 remain disease free in the bladder (47%). Twenty-two have relapsed in the bladder, of whom 5 have also relapsed at metastatic sites. Fifteen patients have relapsed outside the bladder whilst remaining disease free within the bladder. At the time of last follow up or death from other causes 63 of the 100 patients who had a complete response remained disease free with an intact bladder. There were 18 (11%) partial responders. Seven of these patients went on to have a cystectomy. Ten remain alive, 7 disease free, 4 with intact bladders. In 24 patients (15%) there was no response and these patients have all died, the median survival being 10 months. In 21 patients (13%) a postradiotherapy cystoscopy was not performed. In all but one patient, who was lost to follow up, this was because of progressive disease. The median survival of these 20 patients was 6 months. Of the 163 patients 35% are alive and well with an intact bladder. If patients dying from other causes are included then 42% were rendered disease free. Cause specific survival was significantly related to stage of disease at presentation with 5 year actuarial survival being 87%, 48% and 26%, for T1, T2 and T3 disease respectively. Survival was also related to response to treatment at 6 months with 5 year survival being 64%, and 52% for complete and partial responders respectively. Survival was extremely poor for non-responders with only 37.5% surviving 1 year and none 5 years. There was a highly significant relationship between response and the development of, and the time to developing metastatic disease. Of those who exhibited a response 21% developed metastatic disease compared to 78% of non-responders. Salvage cystectomy offers the possibility of cure in those who achieve a complete or partial response with 42% of such patients being rendered disease free. Results however are poor in those who did not respond with all patients dying of their disease. Response rates for all stages, and survival for stages T1 and T2 are much improved from those previously reported from this centre and compare favourably with other published series. These results confirm the place of radiotherapy and salvage cystectomy in the management of TCC of the bladder in selected patients. In about one-third of patients the desired outcome of curing the patient of their cancer with organ preservation is achieved. The prognostic significance of cystoscopic response at 6 months and stage at presentation is confirmed. The outcome for patients with early stage disease is excellent. The relationship between response and the development of metastatic disease would suggest that even if these patients had had a primary cystectomy they may have fared badly, a conclusion supported by the fact that these results are comparable with surgical series. This series supports the role of radiotherapy in the management of this disease and suggests that modern RT techniques including CT planning have had a beneficial effect on the results of radical radiotherapy.
本研究的目的是根据我们放疗计划程序的变化,特别是CT计划的引入,回顾我们对膀胱移行癌(TCC)采用原发性放射治疗(RT)和挽救性膀胱切除术的政策结果。检查了163例采用CT计划技术接受根治性放疗的患者的病历。评估的主要终点是治疗完成后6个月膀胱镜检查时的反应。此外,根据疾病分期和首次膀胱镜检查时的反应估计生存率。分析复发模式和复发时间。文中引用的所有百分比均以最初的163例患者为分母。100例患者(61%)达到完全缓解。完全缓解率与初次就诊时的T分期显著相关,T1期为90%,T2期为75%,T3期为53%。在这些患者中,78例膀胱内无疾病(47%)。22例在膀胱内复发,其中5例也有远处转移。15例在膀胱外复发,而膀胱内仍无疾病。在最后一次随访或因其他原因死亡时,100例完全缓解的患者中有63例膀胱完整且无疾病。有18例(11%)部分缓解者。其中7例患者随后接受了膀胱切除术。10例仍存活,7例无疾病,4例膀胱完整。24例患者(15%)无反应,这些患者均已死亡,中位生存期为10个月。21例患者(13%)未进行放疗后膀胱镜检查。除1例失访患者外,其他患者均因疾病进展未进行检查。这20例患者的中位生存期为6个月。163例患者中,35%膀胱完整且状况良好地存活。如果将因其他原因死亡的患者包括在内,则42%的患者无疾病。特定病因生存率与初次就诊时的疾病分期显著相关,T1、T2和T3期疾病的5年精算生存率分别为87%、48%和26%。生存率也与6个月时的治疗反应相关,完全缓解者和部分缓解者的5年生存率分别为64%和52%。无反应者的生存率极差,仅37.5%的患者存活1年,无患者存活5年。反应与远处转移疾病的发生及发生时间之间存在高度显著的关系。有反应者中21%发生远处转移疾病,而无反应者中这一比例为78%。挽救性膀胱切除术为那些达到完全或部分缓解的患者提供了治愈的可能性,42%的此类患者无疾病。然而,无反应者的结果很差,所有患者均死于该疾病。所有分期的反应率以及T1和T2期的生存率比该中心先前报告的结果有很大改善,与其他已发表的系列相比也更有利。这些结果证实了放疗和挽救性膀胱切除术在特定患者膀胱TCC管理中的地位。在大约三分之一的患者中,实现了通过保留器官治愈患者癌症的理想结果。证实了6个月时膀胱镜检查反应和初次就诊时分期的预后意义。早期疾病患者的结果极佳。反应与远处转移疾病发生之间的关系表明,即使这些患者接受了原发性膀胱切除术,他们的预后可能也很差,这些结果与手术系列结果相当这一事实支持了这一结论。本系列研究支持放疗在该疾病管理中的作用,并表明包括CT计划在内的现代放疗技术对根治性放疗结果产生了有益影响。